Rehabilitation After Treatment

  • Simone Seppi
  • Elena Marta Mancon
  • Rossella Pagliaro


Clostridium histolyticum collagenase injection is a mini-invasive and new treatment for Dupuytren’s disease. It is used in the USA and in Europe as an alternative treatment to partial fasciectomy (Gilpin et al., J Hand Sur 35:2027–2038, 2010; Pajardi et al., Riv Chir Mano 50:5, 2013; Badalamente and Hurst, J Hand Surg Am 32:767–774, 2007; Thomas and Bayat, Therap Clin Risk Manag 6:557–572, 2010; Peimer et al., J Hand Surg 38:12–22, 2013)).

Upper limb surgery usually needs specifically rehabilitation and this technique too.

Edema, pain, hematoma, skin laceration, and even joint’s stiffness are some of the principal symptoms that patients normally have. Especially in these cases, it is important to take charge of the patient as soon as possible to have a better result.

The aim of this chapter is to show our rehabilitation approach after enzymatic fasciectomy for Dupuytren’s disease (Dupuytren, Lancet 2:222–225, 1834; Burge, Hand Clinics 15:63–71, 1999; Beck, Monatschr Unfallheilkd 57: 69–82, 1954)).


  1. 1.
    Dupuytren G. Permanent retraction of the fingers, produced by an affection of the palmar fascia. Lancet. 1834;2:222–5.Google Scholar
  2. 2.
    Burge P. Genetic of Dupuytren’s disease. Hand Clin. 1999;15(1):63–71.PubMedGoogle Scholar
  3. 3.
    Beck W. Untersuchungen über die Häufigkeit der Dupuytrenschen Kontraktur. Monatschr Unfallheilkd. 1954;57:69–82.Google Scholar
  4. 4.
    Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg. 2010;35(12):2027–38.CrossRefGoogle Scholar
  5. 5.
    Pajardi G, Parolo C, Cavalli E, Ponti V. Collagenasi: report preliminare. Riv Chir Mano. 2013;50(1):5.Google Scholar
  6. 6.
    Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren’s contracture. J Hand Surg Am. 2007;32(6):767–74.CrossRefPubMedGoogle Scholar
  7. 7.
    Thomas A, Bayat A. The emerging role of clostridium histolyticum collagenase in the treatment of Dupuytren disease. Ther Clin Risk Manag. 2010;6:557–72.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Peimer CA, Blazar P, Coleman S, Thomas F, Kaplan D, Smith T, Tursi JP, Cohen B, Kaufman GJ, Lindau T. Dupuytren contracture relapse following treatment with collagenase clostridium histolyticum (CORDLESS study): 3-year data. J Hand Surg. 2013;38(1):12–22.CrossRefGoogle Scholar
  9. 9.
    Hurst LC, Badalamente M. Associated disease. In: McFarlane RM, McGrouther DA, Flint MH, editors. Dupuytren’s disease. Edinburgh: Churchill Livingstone; 1990. p. 253–60.Google Scholar
  10. 10.
    Conway H. Dupuytren’s contracture. Am J Surg. 1954;87:101–19.CrossRefPubMedGoogle Scholar
  11. 11.
    Flint MH. Dupuytren’s disease. Edinburgh: Churchill Livingstone; 1990. p. 136–54.Google Scholar
  12. 12.
    Ghazi MR. Dupuytren disease: anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am. 2007;89(1):189–98.CrossRefGoogle Scholar
  13. 13.
    Mackin EJ, Skirven TM. Hand therapy. In: Tubiana R, Leclercq C, Hurst LC, Badalamente MA, Mackin EJ, editors. Dupuytren’s disease. London: Martin Dunitz Ltd; 2000. p. 251–63.Google Scholar
  14. 14.
    Watt AJ, Curtin CM, Hentz VR. Collagenase injection as nonsurgical treatment of Dupuytren’s disease: 8-year follow-up. J Hand Surg Am. 2010;35(4):534–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Engstrand C, Krevers B, Kvist J. Factors affecting functional recovery after surgery and hand therapy in patient with Dupuytren’s disease. J Hand Ther. 2015;28(3):255–60.CrossRefPubMedGoogle Scholar
  16. 16.
    Rodriguez J, Becker G, Ball C, Zhang W, Giele H, Hobby J, Pratt A, Davis T. Surgery for Dupuytren’s contracture of the finger. Cochrane Database Syst Rev. 2015;(12):CD010143.
  17. 17.
    Evans R. Therapeutic management of Dupuytren’s contracture. In:Rehabilitation of hand and upper extremity, vol. 1. 6th ed. Philadelphia: Mosby Elsevier; 2011.Google Scholar
  18. 18.
    Herweijer H, Dijkstra UP, Nicolai JA, van der Sluis CK. Postoperative hand therapy in Dupuytren’s disease. Disabil Rehabil. 2007;29(22):1736–41.CrossRefPubMedGoogle Scholar
  19. 19.
    Shaunak SD, Vincent RH. The treatment of Dupuytren disease. J Hand Surg. 2011;36(5):936–42.CrossRefGoogle Scholar
  20. 20.
    Larson D, Jerosch-Herold C. Clinical effectiveness of post-operative splinting after surgical release of Dupuytren’s contracture: a systematic review. BMC Musculoskelet Disord. 2008;9:104.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Warwick D, Pajardi G. Dupuytren’s disease. Fessh instructional course. Torino: CG Ed Medico Scientifiche; 2015.Google Scholar
  22. 22.
    Gontran RS. Fasciectomy for treatment of Dupuytren’s disease and early complications. J Hand Surg. 1990;15(5):755–61.CrossRefGoogle Scholar
  23. 23.
    Bulstrode NW, Jemec B, Smith PJ. The complications of Dupuytren’s contracture surgery. J Hand Surg. 2005;30(5):1021–5.CrossRefGoogle Scholar
  24. 24.
    Berto GM, Filistad E, Menegari A, di Dupuytren M, Pajardi G. Chirurgia e riabilitazione della mano. Padua: Piccin; 2014. p. 337–52.Google Scholar
  25. 25.
    Zyluk A, Jagielski W. The effect of the severity of the Dupuytren’s contracture on the function of the hand before and after surgery. J Hand Surg. 2007;32(3):326–9.CrossRefGoogle Scholar
  26. 26.
    Tocco S, Pedrazzini A, Pogliacomi S. Clinical approach in PIPJ flexion contracture conservative treatment: our experience. Off J Soc Med Nat Sci Parma. 2016;87(1-S):101–11.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Simone Seppi
    • 1
  • Elena Marta Mancon
    • 1
  • Rossella Pagliaro
    • 1
  1. 1.Department of Hand SurgeryS. Giuseppe MultiMedica Hospital, Università degli Studi MilanoMilanoItaly

Personalised recommendations